1. United States
2. Wash.
3. Letter

The Novavax COVID-19 vaccine represents an important alternative to mRNA vaccines, offering a protein-based approach. Recent concerns raised by the U.S. Health and Human Services Secretary about the vaccine's efficacy appear unfounded, given the comprehensive data submitted by Novavax demonstrating its safety and effectiveness in preventing COVID-19. Delaying approval could undermine public confidence in all COVID-19 vaccines and hinder efforts to protect public health. An objective review of the scientific evidence supports approving the Novavax vaccine to provide an additional option and promote vaccine equity and access. Timely approval is crucial to maintain faith in the regulatory process and expand vaccination coverage.